Skip to main content
. 2020 Sep 11;20(5):227. doi: 10.3892/ol.2020.12090

Figure 1.

Figure 1.

BCLAF1 expression is upregulated in A549/DDP cells. (A) MTT assays were used to measure the sensitivity of A549/WT and A549/DDP cells to cisplatin. Cells were treated with different concentrations of cisplatin for 36 h. *P<0.05, **P<0.01, ***P<0.001 vs. A549/WT. (B) BRCA1, BACH1 and BCLAF1 protein expression levels were measured in A549/WT and A549/DDP cells by western blotting and (C) were quantified. *P<0.05, ***P<0.001. (D) A549/WT and A549/DDP cells were treated continuously with either 0 or 4 µM cisplatin for 10 h, following which BRCA1, BACH1 and BCLAF1 protein expression were examined by western blotting. (E) BCLAF1 mRNA expression was measured using reverse transcription- quantitative PCR in A549/WT and A549/DDP cells. Data are presented as the means ± SD from three independent experimental repeats. *P<0.05, ***P<0.001. DDP, cisplatin resistance; WT, wild-type; BCLAF1, bcl-2- associated transcription factor 1; BACH1, BTB domain and CNC homolog 1.